Pfizer Veteran Mikael Dolsten Joins Maxion to Unlock 'Undruggable' Targets

CAMBRIDGE, United Kingdom – October 20, 2026 – In the high-stakes ecosystem of biopharmaceutical innovation, the movement of elite executive talent often serves as a leading indicator of a technology’s true market potential. When a veteran who has navigated the labyrinth of global drug development at the highest levels chooses to align with an emerging biotech, the industry pays attention. Today, Maxion Therapeutics announced a move that signals precisely this kind of validation: the appointment of Mikael Dolsten, MD, PhD, as an independent Non-Executive Director to its Board.

Dr. Dolsten is not merely an industry participant; he is one of its chief architects. Retiring in March 2025 after a 16-year tenure as Chief Scientific Officer and President of Worldwide Research, Development and Medical at Pfizer, he oversaw the regulatory approval of approximately 40 medicines and vaccines. His portfolio includes managing the unprecedented scale and speed of the COMIRNATY® COVID-19 vaccine and the PAXLOVID® antiviral program. Now, Dolsten is bringing his decades of global drug development expertise to Maxion, a Cambridge-based biotechnology company attempting to solve one of the most persistent structural challenges in modern pharmacology.

The Pfizer Playbook Enters the Boardroom

For Maxion Therapeutics, securing Dolsten’s guidance represents a critical inflection point. The company is actively transitioning from a preclinical research organization into a clinical-stage biotechnology firm, a perilous crossing where many promising startups falter. Dolsten’s deep experience translating scientific innovation into life-changing medicines provides Maxion with an operational blueprint forged at the highest echelons of Big Pharma.

“Mikael has spent his career shaping development strategies for some of the industry’s most innovative medicines, including first-in-class modalities that have delivered meaningful impact for patients worldwide,” commented Eva-Lotta Allan, Chair of the Board of Maxion. “As the CSO at Pfizer, Mikael demonstrated a proven ability to rapidly drive cutting edge science into successful development programmes, moving novel therapies through clinical evaluation to commercialisation and ultimately to patients in need. His expertise and scientific leadership will be instrumental as we advance our proprietary pipeline of KnotBody® therapeutics for autoimmune diseases, heart disorders, and acute and chronic pain into the clinic and we welcome him to the Board.”

Since his departure from Pfizer, Dolsten has carefully curated his post-executive portfolio, focusing heavily on strategic leadership, artificial intelligence in drug discovery, and next-generation biologics. He currently holds board positions at major players like Novo Nordisk and Agilent Technologies, alongside advisory roles for venture powerhouses such as ARCH Venture Partners and Blackstone Life Sciences. His decision to dedicate time to Maxion underscores a strong belief in the company’s foundational science.

Furthermore, his presence significantly bolsters Maxion’s partnership potential. Armed with a $72 million Series A financing round secured in March 2025—led by General Catalyst with participation from Eli Lilly and Company—Maxion has the financial runway to push its lead assets through the end of 2028. Industry analysts note that Dolsten's vast network and track record in forging corporate transactions will be an invaluable asset as the company seeks strategic alliances to co-develop or commercialize its discoveries.

Unlocking the 'Undruggable' Membrane

To understand why a veteran of Dolsten’s caliber is drawn to Maxion, one must look at the biological frontier the company is attempting to conquer: ion channels and G protein-coupled receptors (GPCRs).

These complex membrane proteins are the gatekeepers of cellular communication. Ion channels represent about 1.5 percent of the human genome, while GPCRs account for roughly 4 percent. Together, they are implicated in a vast array of debilitating human conditions, from severe autoimmune disorders to chronic pain and cardiovascular disease. Despite their obvious therapeutic value—annual global sales for ion channel-related drugs alone exceed £12 billion—they remain notoriously difficult to target effectively.

Historically, the pharmaceutical industry has relied on small molecules to modulate these proteins. However, small molecules often bind promiscuously, interacting with multiple unintended targets and causing severe off-target toxicities. Biologics, particularly monoclonal antibodies, offer the exquisite selectivity needed to avoid these side effects. Yet, conventional antibodies are often too large and structurally inflexible to access the hidden, complex binding pockets of ion channels and GPCRs. To date, there are no approved antibody drugs specifically targeting ion channels.

Maxion’s proprietary solution is the KnotBody platform, an elegant feat of protein engineering that fuses venom-derived miniproteins, known as knottins, with standard antibody scaffolds. In nature, knottins are incredibly potent and selective modulators of ion channels, but they possess poor pharmacokinetic properties, meaning they are cleared from the human body too quickly to be effective drugs on their own.

By grafting these knottins onto the binding loops of antibodies, Maxion has created a hybrid molecule. The resulting KnotBody retains the laser-focused functional activity of the knottin while inheriting the long-lasting durability, stability, and superior safety profile of the antibody.

“Maxion’s KnotBody® platform offers an exciting opportunity to develop selective, long-acting biologics against ion channels and GPCRs that have been difficult to address with conventional antibodies,” said Mikael Dolsten, MD, PhD, Non-Executive Director of the Maxion Board. “I look forward to working with the team to translate this scientific potential into differentiated medicines, with a clear focus on clinical development and meaningful benefits for patients.”

A Pipeline Poised for Clinical Reality

The theoretical elegance of the KnotBody platform is now being subjected to the rigorous demands of clinical translation. Maxion is not operating in a vacuum; the race to drug complex membrane proteins includes players like Abilita Therapeutics and SYnAbs, alongside broader nanobody developers. However, Maxion’s specific fusion approach offers a highly differentiated path forward.

The company's lead program, designated MAX001, is currently advancing through late-stage preclinical development. Engineered to target a broad spectrum of inflammatory and autoimmune diseases—including atopic dermatitis and inflammatory bowel disease—MAX001 represents the first major test of the KnotBody hypothesis in human subjects. Additional early-stage programs are actively being co-developed to address acute and chronic pain, as well as cardiovascular conditions, areas where non-addictive and highly specific interventions are desperately needed.

The appointment of Helen Timmis as Vice President of Clinical Development earlier in 2026 signaled the company’s operational pivot toward human trials. Now, with Dolsten providing board-level oversight, Maxion’s clinical strategy will benefit from a level of scrutiny and optimization typically reserved for late-stage pharmaceutical assets. Market observers suggest that having a former Big Pharma R&D chief reviewing trial designs and regulatory strategies can significantly de-risk early-stage clinical execution, helping startups avoid the costly delays that often plague novel modalities.

The Convergence of Scale and Agility

The narrative of modern biotechnology is increasingly defined by this exact synthesis: the marriage of highly agile, platform-driven startups with the operational wisdom of seasoned pharmaceutical veterans. Maxion Therapeutics, co-founded by antibody phage display pioneer Dr. John McCafferty and Dr. Aneesh Karatt-Vellatt, has always possessed elite scientific pedigree. The addition of Mikael Dolsten bridges the crucial gap between scientific invention and commercial realization.

As the biopharmaceutical industry continues to exhaust the easily druggable targets, the future belongs to platforms capable of engineering solutions for the complex, the hidden, and the historically intractable. By combining the evolutionary perfection of venom-derived miniproteins with the proven architecture of therapeutic antibodies, Maxion is betting that the 'undruggable' label is merely a temporary engineering hurdle. With one of the industry's most successful R&D leaders now helping to steer the ship, that bet looks increasingly well-calculated. The coming years will reveal whether the KnotBody platform can deliver on its immense promise, but the strategic pieces required for a biomedical breakthrough are now firmly in place.